BUSINESSQUARTZ
Cancer drug startup Parabilis Medicines is raising a record $670 million in its IPO
Parabilis Medicines, a Cambridge, Massachusetts-based biotech, is raising $670 million in its IPO by pricing 33.5 million shares at $20 each, surpassing Kailera Therapeutics' previous record of $625 million raised in April.
Mentioned
Related Signal
Adjacent reporting
- STAT+: CREATE Medicines, a biotech company developing CAR-T therapies, raises $122 million
- Novo-Backed Biotech Hemab Seeks to Raise $212 Million in US IPO
- STAT+: Longevity startup NewLimit raises $435 million ahead of first clinical trial
- Robotics startup Generalist AI is raising $400 million at a $2 billion valuation
- Ramp raises $750M at $44B valuation as investors hunger for fintechs with an AI story
- Hark raises $700M Series A for its secretive “universal” AI interface